A Phase 1, Multicenter, Open-label, Dose- Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion At the RP2D in Patients with Advanced Solid Tumors
Latest Information Update: 05 Jun 2025
At a glance
- Drugs Adrixetinib (Primary)
- Indications Colon cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Qurient Co
Most Recent Events
- 30 Apr 2025 Results (n=51; as of 11 Jun 2024) presented at the 116th Annual Meeting of the American Association for Cancer Research
- 27 Nov 2024 Status changed from recruiting to active, no longer recruiting.
- 29 Dec 2023 Planned End Date changed from 18 Nov 2023 to 28 Feb 2025.